| P2093 | author name string | Gene P Siegal | |
| | Shi Wei | |
| P2860 | cites work | Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1 | Q24300916 |
| | A protein kinase involved in the regulation of inflammatory cytokine biosynthesis | Q24311139 |
| | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor | Q24563111 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Impaired differentiation of osteoclasts in TREM-2-deficient individuals | Q24672735 |
| | A novel member of the leukocyte receptor complex regulates osteoclast differentiation | Q24675157 |
| | Osteoclasts: what do they do and how do they do it? | Q24683898 |
| | Bone resorption by osteoclasts | Q28145169 |
| | Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction | Q28191438 |
| | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients | Q73880310 |
| | Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells | Q74520565 |
| | Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States | Q74552365 |
| | Interleukin-1 | Q74629939 |
| | Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction | Q75288496 |
| | Regulation of interleukin-1beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by glucocorticoids | Q77614935 |
| | Variation in the TNF gene promoter and risk of osteolysis after total hip arthroplasty | Q79271031 |
| | Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts | Q79429250 |
| | MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation | Q80086917 |
| | Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate | Q80201780 |
| | Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial | Q80207327 |
| | Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition | Q81216018 |
| | New therapies for systemic lupus erythematosus | Q81609248 |
| | Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction | Q82424436 |
| | Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats | Q83033747 |
| | A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis | Q83101988 |
| | The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial | Q83223892 |
| | The treatment of rheumatoid arthritis: Getting better all the time? | Q57350047 |
| | RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β | Q57675150 |
| | Marrow Stromal Cells and Osteoclast Precursors Differentially Contribute to TNF- -Induced Osteoclastogenesis In Vivo | Q58085384 |
| | Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling | Q58085461 |
| | c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling | Q58326943 |
| | The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene | Q59092154 |
| | Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement | Q70301361 |
| | Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells | Q73075587 |
| | Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthr | Q73202432 |
| | The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts | Q73323617 |
| | Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor | Q73490934 |
| | Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis | Q28202653 |
| | Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer | Q28211178 |
| | In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis | Q28216662 |
| | Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function | Q28253289 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells | Q28591227 |
| | Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption | Q28592760 |
| | p38 MAPK signalling cascades in inflammatory disease | Q28678986 |
| | Genetic regulation of osteoclast development and function | Q29617421 |
| | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 |
| | Transcriptional regulation by calcium, calcineurin, and NFAT | Q29620410 |
| | Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors | Q31958046 |
| | Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. | Q32006878 |
| | A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency | Q33340517 |
| | Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? | Q33937489 |
| | M-CSF mediates TNF-induced inflammatory osteolysis | Q34133595 |
| | Stem cells for repair of cartilage and bone: the next challenge in osteoarthritis and rheumatoid arthritis | Q34180331 |
| | Fas binding to calmodulin regulates apoptosis in osteoclasts | Q34312838 |
| | Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology | Q34325803 |
| | Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 |
| | Periodontal diseases. | Q34468885 |
| | Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial | Q34559671 |
| | Osteoclasts are essential for TNF-alpha-mediated joint destruction | Q34826003 |
| | Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis? | Q34866114 |
| | The mode of action of cytokine inhibitors | Q34866129 |
| | Bone destruction in arthritis. | Q34963176 |
| | Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis | Q34967810 |
| | The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis | Q35094697 |
| | Gene therapy for arthritis | Q35122176 |
| | Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 |
| | Novel bone-targeted Src tyrosine kinase inhibitor drug discovery | Q35568263 |
| | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. | Q35638252 |
| | Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium | Q35749232 |
| | Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? | Q35951845 |
| | Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab | Q35954629 |
| | New therapies for rheumatoid arthritis | Q36088346 |
| | Pathological role of osteoclast costimulation in arthritis-induced bone loss. | Q36090203 |
| | The biology of p38 kinase: a central role in inflammation | Q36264558 |
| | Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival | Q36282204 |
| | Small molecular anti-cytokine agents. | Q36311663 |
| | New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. | Q36384990 |
| | Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis | Q36402845 |
| | Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes | Q36410818 |
| | Bisphosphonate therapy in rheumatoid arthritis | Q36450042 |
| | Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases | Q36494210 |
| | Inflammation-induced bone remodeling in periodontal disease and the influence of post-menopausal osteoporosis | Q36518539 |
| | Mitogen activated protein kinase inhibitors: where are we now and where are we going? | Q36622407 |
| | Application of cellular gene therapy for rheumatoid arthritis | Q36622653 |
| | Interleukin 6: from bench to bedside | Q36639873 |
| | p38 MAPK as a potential therapeutic target for inflammatory osteolysis | Q36696808 |
| | The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons | Q36810833 |
| | New therapies for treatment of rheumatoid arthritis | Q36849874 |
| | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 |
| | A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats | Q37242322 |
| | TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand | Q37413745 |
| | The problem is osteolysis | Q40459888 |
| | A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis | Q40550916 |
| | Effect of pamidronate on the stimulation of macrophage TNF-alpha release by ultra-high-molecular-weight polyethylene particles: a role for apoptosis | Q40680084 |
| | IL-1 mediates TNF-induced osteoclastogenesis | Q40909592 |
| | Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. | Q41121255 |
| | The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. | Q41850515 |
| | Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation | Q42475736 |
| | A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. | Q43984055 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Concomitant recruitment of ERK1/2 and p38 MAPK signalling pathway is required for activation of cytoplasmic phospholipase A2 via ATP in articular chondrocytes | Q44319464 |
| | Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis | Q44514609 |
| | Gene therapy. Seeking the cause of induced leukemias in X-SCID trial | Q45858033 |
| | Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis | Q47761859 |
| | The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. | Q51126431 |
| | Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 |
| | Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. | Q54041247 |
| | Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. | Q54528791 |
| | Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion | Q56904375 |
| P433 | issue | 10 | |
| P921 | main subject | osteolysis | Q2035084 |
| | inflammation | Q101991 |
| P304 | page(s) | 695-706 | |
| P577 | publication date | 2008-08-30 | |
| P1433 | published in | Pathology, Research and Practice | Q15758752 |
| P1476 | title | Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets | |
| P478 | volume | 204 | |